🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06510036
Recruiting Observational

Assessment of Pancreatic Physiological and Pathological Characteristics Based on Spectral CT

NCT06510036 · tracked via the Priya Life Science China tracker
Sponsor
Yu Shi
Phase
Observational
Started
2021-01-21
Last updated
2024-12-04

Condition(s) studied

Diagnose Disease

Investigational drug(s) / intervention(s)

The post-processing generated after scanning is converted into energy spectrum image data (SBI)

The post-processing generated after scanning is converted into energy spectrum image data (SBI): It will not open special sequences for patients, will not increase the cost of diagnosis and treatment, will not increase radiation exposure during enhanced CT scanning, and will not affect the normal diagnosis and treatment process of patients throughout the process.

Study summary

Patients who visited our hospital for various reasons from January 2024, underwent CT scans involving the pancreas, and were eligible for spectral post-processing reconstruction were included in the study. This research collected spectral CT data related to the pancreas at different phases, as well as physiological and pathological states for these patients. Quantitative analysis was conducted on post-processed data under different physiological and pathological states, including parameters such as pancreatic iodine uptake features, attenuation interval slopes, and extracellular volume size. In conjunction with general patient status, biochemical tests, and postoperative pathological results, the study aimed to identify correlations between parameters, develop models, and conduct research by comparing traditional CT data, which could be matched with spectral CT from the PACS database since its establishment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1.Since March 2024, I have been visiting our hospital for various reasons and have undergone CT scans involving the pancreas (using energy spectrum CT) Exclusion Criteria: 1. Previous pancreatic surgery with incomplete pancreatic tissue. 2. Severe systemic diseases that result in severe organ dysfunction 3. Excessive pancreatic atrophy or other reasons cannot accurately delineate ROI

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shengjing Hospital of China Medical University Shenyang Liaoning Recruiting

More Yu Shi trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06510036 on ClinicalTrials.gov ↗ ← All trials in China